- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02577237
Building Caregiver Skills Using a Simulation-based Intervention for Care of Head and Neck Cancer
Building Family Caregiver Skills Using a Simulation-based Intervention for Care of Patients With Head and Neck Cancer
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Aim 1: Conduct a pilot test of the effects of a novel caregiver intervention, as compared to a control group, on family caregiver self-efficacy for caregiving, anxiety, depression, and health-related quality of life.
Aim 2: Explore the acceptability of a caregiver intervention that utilizes simulation.
Aim 3: Assess the feasibility of the intervention. Aim 4: Describe the incidence of patient events that may be impacted by caregiver self-efficacy, such as acute care visits, admissions to the hospital, visits to the emergency department, need for fluids in the radiation oncology department, and interrupted treatment course.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44106
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- family member or friend of an adult patient with a new diagnosis of Stage III - IV cancers of the tongue, gum, oral cavity, nasopharynx, oropharynx, hypopharynx, larynx, or parotid who is receiving radiation therapy for curative intent
- identified by the patient as his/her primary caregiver who is providing daily assistance and/or emotional support
- cognitively intact, as evidenced by orientation to person, place, and time
- ability to speak, read, and comprehend English
Exclusion Criteria:
- Caregivers of patients who are receiving hospice care will be excluded because of the patient's poor prognosis and multiple issues associated with end-of-life care
- Caregivers who are themselves undergoing active cancer treatment will be excluded (hormonal treatment allowed)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intervention Group: Caregiver education
The intervention includes caregivers who will receive an education and support program throughout radiation treatment in addition to usual care by their doctors and nurses.
|
The intervention will be delivered by a radiation oncology nurse.
Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
Altri nomi:
written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
Altri nomi:
|
|
Comparatore attivo: Control Group: educational booklet
The control group will receive an educational booklet about caregiving in addition to usual care by their doctors and nurses
|
written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
Altri nomi:
Radiation Oncology Nurse will hand participant the NCI booklet
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Average efficacy of caregiving summary score
Lasso di tempo: Up to 5 weeks
|
Summary statistics as well as observed values of longitudinally measured efficacy outcome variables (efficacy for caregiving, anxiety, depression, and HRQOL) will be presented graphically.
Linear mixed models will be used to estimate within- and between-subject components of variance needed for design of a larger trial with these endpoints.
|
Up to 5 weeks
|
|
Average anxiety summary score
Lasso di tempo: Up to 5 weeks
|
Summary statistics as well as observed values of longitudinally measured efficacy outcome variables (efficacy for caregiving, anxiety, depression, and HRQOL) will be presented graphically.
Linear mixed models will be used to estimate within- and between-subject components of variance needed for design of a larger trial with these endpoints.
|
Up to 5 weeks
|
|
Average depression summary score
Lasso di tempo: Up to 5 weeks
|
Summary statistics as well as observed values of longitudinally measured efficacy outcome variables (efficacy for caregiving, anxiety, depression, and HRQOL) will be presented graphically.
Linear mixed models will be used to estimate within- and between-subject components of variance needed for design of a larger trial with these endpoints.
|
Up to 5 weeks
|
|
Average Health Related Quality of Life (HRQOL) summary score
Lasso di tempo: Up to 5 weeks
|
Summary statistics as well as observed values of longitudinally measured efficacy outcome variables (efficacy for caregiving, anxiety, depression, and HRQOL) will be presented graphically.
Linear mixed models will be used to estimate within- and between-subject components of variance needed for design of a larger trial with these endpoints.
|
Up to 5 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Qualitative assessment of acceptability
Lasso di tempo: Up to 5 weeks
|
Descriptive statistics will be used to summarize responses to semi-structured interviews
|
Up to 5 weeks
|
|
Attrition rate to assess feasibility
Lasso di tempo: Up to 5 weeks
|
Feasibility will be assessed via attrition and consent rates.
|
Up to 5 weeks
|
|
Consent rate to assess feasibility
Lasso di tempo: Up to 5 weeks
|
Feasibility will be assessed via attrition and consent rates.
|
Up to 5 weeks
|
|
Total time for delivering intervention to assess costs
Lasso di tempo: Up to 5 weeks
|
Time for delivering the intervention will be recorded to aid in assessing costs.
|
Up to 5 weeks
|
|
Average missed checklist items to assess integrity of intervention
Lasso di tempo: Up to 5 weeks
|
Integrity of the intervention will be assessed through monitoring of intervention checklist.
|
Up to 5 weeks
|
|
Event rate for patient events
Lasso di tempo: Up to 5 weeks
|
Describe the average incidence of all patient events that may be impacted by caregiver self-efficacy.
Events may include acute care visits, admission to the hospital, visits to the emergency department, need for fluids in the radiation oncology department, and interrupted treatment course, and others
|
Up to 5 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Susan Mazanec, PhD, RN, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CASE2315
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su In-person education sessions
-
Nordsjaellands HospitalLund University; Region Capital Denmark; Ostfold University College; University College... e altri collaboratoriReclutamentoOspedaleDanimarca, Norvegia, Svezia
-
Göteborg UniversityCompletatoQualità della vita correlata alla salute
-
Tokat Gaziosmanpasa UniversityCompletatoStigmatizzazione | Funzionalità | Supporto tra pari | Disturbi mentali cronici | Formazione sulle abilità psicosociali | IntuizioneTacchino
-
Tulane UniversityUniversity of Alabama at Birmingham; Louisiana State University Health Sciences... e altri collaboratoriTerminatoCOVID-19 | Lupus eritematoso sistemicoStati Uniti
-
Fundacion para la Investigacion y Formacion en...Iscrizione su invitoBPCO (broncopneumopatia cronica ostruttiva)Spagna
-
National University of Ireland, Galway, IrelandUniversity College Hospital Galway; Brothers of Charity Services Galway IrelandNon ancora reclutamentoDisabilità intellettive (F70-F79) | Educazione alla prevenzione e alla consapevolezza del cancro | Consapevolezza del cancro al senoIrlanda
-
Saglik Bilimleri UniversitesiNon ancora reclutamentoInvecchiamento | Anziani fragili | Sindromi geriatriche
-
University of California, Los AngelesTerminatoUtilizzo dell'assistenza sanitaria | Carcerazione giovanileStati Uniti
-
Centers for Disease Control and PreventionCompletatoInfezioni da HIV | Epatite CStati Uniti
-
University of Arkansas, FayettevilleNational Cancer Institute (NCI); University of California, Los Angeles; Thomas... e altri collaboratoriAttivo, non reclutanteMalattie prevenibili da vaccino | Papilloma-virus umanoStati Uniti